Sonosemi: A Rising Star in Global MedTech with Breakthrough Intravascular Lithotripsy System

Apr 23, 2024 00:01 CST Updated 00:01

SONOSEMI

Active Vascular Implantable and Interventional Medical Device R&D and Manufacturer

Si YuMedTechIn2024A batch was selected at the beginning of the year.2023Annual Outstanding Enterprises and Products,Among themSONOSEMICompany wasGrant“2023Global MedTech Newcomer Award (2023 Global MedTech Rising Star Award）”。

The reason for winning is:SONOSEMI's Self-Developed Coronary Shockwave Lithotripsy System Utilizes Innovative Vascular Calcification Plaque Fracturing Technology, Integrating Traditional Electrohydraulic Lithotripsy and Balloon Angioplasty to Creatively Address Coronary Artery Calcified Lesions. By Pre-Treating the Vessel Lumen and Fracturing Existing Calcified Plaques, the System Significantly Improves Vascular Compliance. This system was approved for marketing by the National Medical Products Administration in October 2023.

Today, Siyu introduces this innovative company to the readers.

# Company Introduction

SONOSEMIFounded in April 2020, headquartered in Shenzhen, is a research and productionActive Vascular Implantable Medical Deviceshigh-tech enterprise, with main businesses coveringCardio-cerebrovascular, Peripheral VascularIn the medical field represented by, the products includeShockwave Balloon Catheter, Ultrasonic CatheterSuch as active interventional high-value medical consumables, the products coverCoronary artery disease, peripheral vascular disease, and structural heart diseaseIn the clinical fields of cardiovascular and cerebrovascular diseases.

SONOSEMI has broken through the technical barriers of high-end medical devices overseas and independently developedCoronary Intravascular Shockwave Therapy System, Peripheral Arterial Intravascular Shockwave Therapy System, Intracardiac Ultrasound Imaging System, Intravascular UltrasoundProducts like the innovative active interventional products for pan-vascular applications are expected to form a product matrix consisting of 4-6 products by the end of 2024, providing customers with comprehensive and integrated solutions.These products extensively cover indications such as coronary artery calcification, peripheral artery calcification, aortic valve stenosis, and structural heart disease.

# CEO Introduction

According to Tianyancha information, the actual controller of SONOSEMI is Liu Bin.SONOSEMI's co-founder and CEO, previously worked at Huawei Technologies, isHuawei EngineerBackground. With years of experience in communication and semiconductor technology research and applications, he has a strong technical background in the industry and holds more than 20 invention patents. He is also a serial entrepreneur with extensive experience in technological innovation, team management, and commercial applications.

Participated in the entrepreneurship of a semiconductor chip company, and through in-depth collaboration with partners in the medical field, rapidly advanced the shock wave balloon, an active interventional product, into the clinical stage. A series of interventional visualization hardware products developed by the company will also successively obtain certifications. The company’s platform-based development strategy is very clear.

# Product Introduction

1. Coronary Artery Shockwave Lithotripsy System

Coronary Artery Lithotripsy System by "LiqMagic C14 Shock Wave Coronary Balloon Catheter" and "ISL100 Pro Intracorporeal Shock Wave Therapy Device"Composed of two parts, the system utilizes an innovativeVascular Calcification Plaque Fracture Technology, achieving a technical fusion of traditional electrohydraulic lithotripsy and balloon angioplasty, which has been creatively applied to the treatment of coronary artery calcified lesions. By preprocessing the vascular lumen, it fractures existing calcified plaques, significantly improving vascular compliance.

▲LiqMagic C14 Shock Wave Coronary Balloon Catheter System

On October 19, 2021, the first clinical enrollment for the "Coronary Artery Shockwave Lithotripsy System" was completed at the Cardiology Department of Tangdu Hospital.
In January 2024, Professor Zhang Haishan from the team of Director Sun Yingxian of the Cardiology Department at the First Affiliated Hospital of China Medical University successfully performed a PCI surgery on a patient with severe coronary artery calcified stenosis using SONOSEMI's self-developed Coronary Intravascular Shockwave Treatment System. The surgery achieved the desired results, and the patient's discomfort significantly improved post-operation.
October 2023，Coronary Artery Lithotripsy SystemApproved for marketing by the National Medical Products Administration.

2. Intracardiac Echocardiography System (ICE)

On May 26, 2023, SONOSEMI independently developedIntracardiac Echocardiography Imaging System (ICE)Approved to enter the National Medical Products Administration (NMPA) special review process for innovative medical devices, this product isThe First China-Made ICE Product Approved to Enter the Innovation Fast Track in China, which has completed the registration clinical research and entered the registration application stage, is highly likely to become the first domestically produced ICE product approved for marketing in China.

SONOSEMI's Intracardiac Echocardiography (ICE) System consists of the UDG3900 Color Doppler Ultrasound Diagnostic System and the DynaSight 2D Single-Use Intracardiac Echocardiography Catheter. It is suitable for intracardiac and large vessel imaging, as well as ultrasound imaging of other devices within the heart.

As of the press release date, SONOSEMI has获批上市产品如下2款.